Prior treatment with siRNA to silence Egr1 expression in vivo reversed the expression of Egr1 target genes, clearly supporting the role of Egr1 as a functional transcription factor in M12 prostate cancer cells. This evidence concerns the gene EGR1 and prostate carcinoma.